Abingworth Bioventures
SelectiveWashington, DCBiotech & pharma, Digital health, Medical devicesLast fund filed December 2023
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Abingworth Bioventures 9 | December 2023 | Indefinite | $320M | 29 |
| Abingworth Bioventures VII | November 2016 | $400M | $240M | 16 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
11 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Shelley ChuNot on the current fund | Selective | Biotech & pharma | 12 | 2 |
| David LeathersNot on the current fund | Quiet | None listed | 0 | 0 |
| David Lobe | Quiet | None listed | 0 | 0 |
| Genghis Lloyd-harrisNot on the current fund | Quiet | Biotech & pharma | 1 | 0 |
| James AbellNot on the current fund | Quiet | None listed | 0 | 0 |
| Ken HaasNot on the current fund | Quiet | Biotech & pharma, Digital health, Medical devices | 3 | 0 |
| Michael BighamNot on the current fund | Quiet | Biotech & pharma, Medical devices | 4 | 0 |
| Robert Rosen | Quiet | Biotech & pharma, Digital health | 3 | 0 |
| Stephen BuntingNot on the current fund | Quiet | None listed | 0 | 0 |
| Timothy HainesNot on the current fund | Quiet | Biotech & pharma | 2 | 0 |
| Vincent MilesNot on the current fund | Quiet | Biotech & pharma | 5 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Categories of Abingworth Bioventures’s own portfolio companies, based on 28 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Abingworth Bioventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Atlas Venture | 7 | Antares Therapeutics, IFM Cinque, IFM Continua, IFM Quattro, IFM Tre, Scorpion Therapeutics, Triana Biomedicines |
| MPM BioVentures | 2 | CHIASMA, PROTEON THERAPEUTICS |
| Omega Funds | 2 | PARATEK PHARMACEUTICALS, Scorpion Therapeutics |
| Sofinnova Venture Partners | 2 | AVEDRO, EFFECTOR THERAPEUTICS |
| Third Rock Ventures | 2 | Abata Therapeutics, Triana Biomedicines |
| Vida Ventures | 2 | Protego Biopharma, Scorpion Therapeutics |
| 270 Healthcare Growth | 1 | Enlaza Therapeutics |
| Arboretum Ventures | 1 | SONITUS MEDICAL |
| Bain Capital Life Sciences | 1 | GYNESONICS |
| Borealis | 1 | AVEDRO |
| Cure Ventures | 1 | PARATEK PHARMACEUTICALS |
| Dimension Capital | 1 | Odyssey Therapeutics |
| Frazier Life Sciences | 1 | Enlaza Therapeutics |
| Healthquest Partners | 1 | AVEDRO |
| Lightspeed Venture Partners | 1 | Personalis |
A shared board seat: a company where filings name a Abingworth Bioventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.